HL7 Terminology (THO)
5.1.0 - Publication
This page is part of the HL7 Terminology (v5.1.0: Release) based on FHIR R4. The current version which supercedes this version is 5.2.0. For a full list of available versions, see the Directory of published versions
Official URL: http://terminology.hl7.org/ValueSet/research-study-phase | Version: 0.1.0 | |||
Draft as of 2020-02-24 | Maturity Level: 1 | Responsible: HL7 (FHIR Project) | Computable Name: ResearchStudyPhase | |
Other Identifiers: id: urn:oid:2.16.840.1.113883.4.642.3.821 |
Codes for the stage in the progression of a therapy from initial experimental use in humans in clinical trials to post-market evaluation.
References
This value set is not used here; it may be used elsewhere (e.g. specifications and/or implementations that use this content)
http://terminology.hl7.org/CodeSystem/research-study-phase
This value set contains 8 concepts
Expansion based on ResearchStudyPhase v0.1.0 (CodeSystem)
Code | System | Display | Definition |
n-a | http://terminology.hl7.org/CodeSystem/research-study-phase | N/A | Trials without phases (for example, studies of devices or behavioral interventions). |
early-phase-1 | http://terminology.hl7.org/CodeSystem/research-study-phase | Early Phase 1 | Designation for optional exploratory trials conducted in accordance with the United States Food and Drug Administration's (FDA) 2006 Guidance on Exploratory Investigational New Drug (IND) Studies. Formerly called Phase 0. |
phase-1 | http://terminology.hl7.org/CodeSystem/research-study-phase | Phase 1 | Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients. |
phase-1-phase-2 | http://terminology.hl7.org/CodeSystem/research-study-phase | Phase 1/Phase 2 | Trials that are a combination of phases 1 and 2. |
phase-2 | http://terminology.hl7.org/CodeSystem/research-study-phase | Phase 2 | Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks. |
phase-2-phase-3 | http://terminology.hl7.org/CodeSystem/research-study-phase | Phase 2/Phase 3 | Trials that are a combination of phases 2 and 3. |
phase-3 | http://terminology.hl7.org/CodeSystem/research-study-phase | Phase 3 | Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug. |
phase-4 | http://terminology.hl7.org/CodeSystem/research-study-phase | Phase 4 | Studies of FDA-approved drugs to delineate additional information including the drug's risks, benefits, and optimal use. |
Explanation of the columns that may appear on this page:
Level | A few code lists that FHIR defines are hierarchical - each code is assigned a level. In this scheme, some codes are under other codes, and imply that the code they are under also applies |
System | The source of the definition of the code (when the value set draws in codes defined elsewhere) |
Code | The code (used as the code in the resource instance) |
Display | The display (used in the display element of a Coding). If there is no display, implementers should not simply display the code, but map the concept into their application |
Definition | An explanation of the meaning of the concept |
Comments | Additional notes about how to use the code |
History
Date | Action | Custodian | Author | Comment |
2020-10-14 | revise | Vocabulary WG | Grahame Grieve | Reset Version after migration to UTG |
2020-05-06 | revise | Vocabulary WG | Ted Klein | Migrated to the UTG maintenance environment and publishing tooling. |